Satellos Bioscience, Inc. — Biomedical Watch V2

Traitements2programmes

Essais1liés

Publications0liées

SourceDBlocale

Traitements

2

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
SAT-3247Phase 2a trial of SAT-3247 in ambulatory DMD patients aged ≥ 7 and \< 10 years. The trial will study two doses of SAT-3247 in a randomized, double-blind, placebo-controlled weekday regimen for 12 weeks to determine the optimal dose, safety, tolerability, and preliminary efficacy.	Myopathies	Phase 2	À vérifier	United States, Australia, Belgium, Canada, Poland, Serbia, Spain, United Kingdom	À vérifier
SAT-3247Phase 2a trial of SAT-3247 in ambulatory DMD patients aged ≥ 7 and \< 10 years. The trial will study two doses of SAT-3247 in a randomized, double-blind, placebo-controlled weekday regimen for 12 weeks to determine the optimal dose, safety, tolerability, and preliminary efficacy.	Myopathies	Phase 2	À vérifier	United States, Australia, Belgium, Canada, Poland, Serbia, Spain, United Kingdom	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
SAT-3247	Myopathies	Phase 2	NCT07287189	BASECAMP — Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients	RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.